Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 294278, 12 pages
http://dx.doi.org/10.1155/2015/294278
Review Article

Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis

Cell, Molecular, and Structural Biology, Department of Biology, Miami University, 700 E. High Street, Oxford, OH 45056, USA

Received 11 May 2015; Revised 5 August 2015; Accepted 9 August 2015

Academic Editor: Małgorzata Kotula-Balak

Copyright © 2015 Minqian Shen and Haifei Shi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U. E. A. Martensson, S. A. Salehi, S. Windahl et al., “Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice,” Endocrinology, vol. 150, no. 2, pp. 687–698, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. D. Home and G. Pacini, “Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents,” Diabetes, Obesity and Metabolism, vol. 10, no. 9, pp. 699–718, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Perry, V. T. Samuel, K. F. Petersen, and G. I. Shulman, “The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes,” Nature, vol. 510, no. 7503, pp. 84–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. C. Carr, “The emergence of the metabolic syndrome with menopause,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2404–2411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Zitzmann, “Testosterone deficiency, insulin resistance and the metabolic syndrome,” Nature Reviews Endocrinology, vol. 5, no. 12, pp. 673–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Lazo and J. M. Clark, “The epidemiology of nonalcoholic fatty liver disease: a global perspective,” Seminars in Liver Disease, vol. 28, no. 4, pp. 339–350, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994,” American Journal of Epidemiology, vol. 178, no. 1, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Williamson, J. F. Price, S. Glancy et al., “Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes study,” Diabetes Care, vol. 34, no. 5, pp. 1139–1144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. E. Kelley, A. J. Brown, A. M. Diehl, and T. L. Setji, “Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome,” World Journal of Gastroenterology, vol. 20, no. 39, pp. 14172–14184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Polyzos, J. Kountouras, A. Tsatsoulis et al., “Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease,” Hormones, vol. 12, no. 3, pp. 405–416, 2013. View at Google Scholar · View at Scopus
  13. L. Carulli, A. Lonardo, S. Lombardini, G. Marchesini, and P. Loria, “Gender, fatty liver and GGT,” Hepatology, vol. 44, no. 1, pp. 278–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. E. R. Simpson, “Sources of estrogen and their importance,” Journal of Steroid Biochemistry and Molecular Biology, vol. 86, no. 3–5, pp. 225–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Shi, S. P. D. S. Kumar, and X. Liu, “G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis,” Progress in Molecular Biology and Translational Science, vol. 114, pp. 193–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Iavarone, P. Lampertico, C. Seletti et al., “The clinical and pathogenetic significance of estrogen receptor-β expression in chronic liver diseases and liver carcinoma,” Cancer, vol. 98, no. 3, pp. 529–534, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Miceli, L. Cocciadiferro, M. Fregapane et al., “Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression,” OMICS, vol. 15, no. 5, pp. 313–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Cui, Y. Shen, and R. Li, “Estrogen synthesis and signaling pathways during aging: from periphery to brain,” Trends in Molecular Medicine, vol. 19, no. 3, pp. 197–209, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Alvaro, G. Alpini, P. Onori et al., “Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats,” Gastroenterology, vol. 119, no. 6, pp. 1681–1691, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. G. G. Kuiper, K. Grandien, E. Enmark, J. Häggblad, S. Nilsson, and J.-Å. Gustafsson, “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and alpha and beta,” Endocrinology, vol. 138, no. 3, pp. 863–870, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. E. R. Lax, P. Tamulevicius, A. Müller, and H. Schriefers, “Hepatic nuclear estrogen receptor concentrations in the rat—influence of age, sex, gestation, lactation and estrous cycle,” Journal of Steroid Biochemistry, vol. 19, no. 2, pp. 1083–1088, 1983. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Eisenfeld and R. F. Aten, “Estrogen receptors and androgen receptors in the mammalian liver,” Journal of Steroid Biochemistry and Molecular Biology, vol. 27, no. 4–6, pp. 1109–1118, 1987. View at Publisher · View at Google Scholar · View at Scopus
  23. M. K. Mohamed and A. A. Abdel-Rahman, “Effect of long-term ovariectomy and estrogen replacement on the expression of estrogen receptor gene in female rats,” European Journal of Endocrinology, vol. 142, no. 3, pp. 307–314, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Finkelstein, H. Lee, S.-A. M. Burnett-Bowie et al., “Gonadal steroids and body composition, strength, and sexual function in men,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1011–1022, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Handgraaf, E. Riant, A. Fabre et al., “Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable,” Diabetes, vol. 62, no. 12, pp. 4098–4108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Ciana, M. Raviscioni, P. Mussi et al., “In vivo imaging of transcriptionally active estrogen receptors,” Nature Medicine, vol. 9, no. 1, pp. 82–86, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Villa, S. Della Torre, A. Stell, J. Cook, M. Brown, and A. Maggi, “Tetradian oscillation of estrogen receptor α is necessary to prevent liver lipid deposition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 29, pp. 11806–11811, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. K. L. Chambliss, Q. A. Wu, S. Oltmann et al., “Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2319–2330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. L. G. Kang, X. T. Zhang, Y. Xie et al., “Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling,” Molecular Endocrinology, vol. 24, no. 4, pp. 709–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. C. Velarde, “Pleiotropic actions of estrogen: a mitochondrial matter,” Physiological Genomics, vol. 45, no. 3, pp. 106–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Nilsson, B. Olde, and L. M. F. Leeb-Lundberg, “G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling,” British Journal of Pharmacology, vol. 163, no. 6, pp. 1131–1139, 2011. View at Publisher · View at Google Scholar
  32. L. Trapani, M. Segatto, and V. Pallottini, “Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic ‘power station’,” World Journal of Hepatology, vol. 4, no. 6, pp. 184–190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. T. M. D'Eon, S. C. Souza, M. Aronovitz, M. S. Obin, S. K. Fried, and A. S. Greenberg, “Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways,” The Journal of Biological Chemistry, vol. 280, no. 43, pp. 35983–35991, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. C. R. Fisher, K. H. Graves, A. F. Parlow, and E. R. Simpson, “Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 12, pp. 6965–6970, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Shen, S. P. Kumar, and H. Shi, “Estradiol regulates insulin signaling and inflammation in adipose tissue,” Hormone Molecular Biology and Clinical Investigation, vol. 17, no. 2, pp. 99–107, 2014. View at Google Scholar
  36. A. Foryst-Ludwig and U. Kintscher, “Metabolic impact of estrogen signalling through ERalpha and ERbeta,” Journal of Steroid Biochemistry and Molecular Biology, vol. 122, no. 1–3, pp. 74–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Courtney, S. Talbot, and R. Manning, “Early effects of oestrogen treatment on lipogenesis de novo and on biosynthesis of triacylglycerol from fatty acids in male chick liver,” International Journal of Biochemistry, vol. 20, no. 1, pp. 73–78, 1988. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Gowri, S. Sengupta, S. Bertera, and B. S. Katzenellenbogen, “Lipin1 regulation by estrogen in uterus and liver: implications for diabetes and fertility,” Endocrinology, vol. 148, no. 8, pp. 3685–3693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Gao, S. Fält, A. Sandelin, J.-Å. Gustafsson, and K. Dahlman-Wright, “Genome-wide identification of estrogen receptor α-binding sites in mouse liver,” Molecular Endocrinology, vol. 22, no. 1, pp. 10–22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Ribas, M. T. A. Nguyen, D. C. Henstridge et al., “Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERalpha-deficient mice,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 298, no. 2, pp. E304–E319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Linnér, J. Svartberg, A. Giwercman, and Y. L. Giwercman, “Estrogen receptor alpha single nucleotide polymorphism as predictor of diabetes type 2 risk in hypogonadal men,” Aging Male, vol. 16, no. 2, pp. 52–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. P. A. Heine, J. A. Taylor, G. A. Iwamoto, D. B. Lubahn, and P. S. Cooke, “Increased adipose tissue in male and female estrogen receptor-α knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12729–12734, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Bryzgalova, H. Gao, B. Ahren et al., “Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver,” Diabetologia, vol. 49, no. 3, pp. 588–597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Zhu, M. N. Martinez, C. H. Emfinger, B. T. Palmisano, and J. M. Stafford, “Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 306, no. 10, pp. E1188–E1197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhu, W. C. Brown, Q. Cai et al., “Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance,” Diabetes, vol. 62, no. 2, pp. 424–434, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Meoli, J. Isensee, V. Zazzu et al., “Sex- and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice,” Gene, vol. 540, no. 2, pp. 210–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. H. Faulds, C. Zhao, K. Dahlman-Wright, and J.-Å. Gustafsson, “The diversity of sex steroid action: regulation of metabolism by estrogen signaling,” Journal of Endocrinology, vol. 212, no. 1, pp. 3–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Lemieux, D. Phaneuf, F. Labrie, V. Giguère, D. Richard, and Y. Deshaies, “Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene,” International Journal of Obesity, vol. 29, no. 10, pp. 1236–1244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. K. N. Hewitt, K. Pratis, M. E. E. Jones, and E. R. Simpson, “Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse,” Endocrinology, vol. 145, no. 4, pp. 1842–1848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Zhang, Y. W. Liu, L. Wang et al., “Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat,” Journal of Lipid Research, vol. 54, no. 2, pp. 345–357, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Pedram, M. Razandi, F. O'Mahony, H. Harvey, B. J. Harvey, and E. R. Levin, “Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling,” Science Signaling, vol. 6, no. 276, p. ra36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Foryst-Ludwig, M. Clemenz, S. Hohmann et al., “Metabolic actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with PPARγ,” PLoS Genetics, vol. 4, no. 6, Article ID e1000108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Weigt, T. Hertrampf, F. M. Kluxen et al., “Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats,” Molecular and Cellular Endocrinology, vol. 377, no. 1-2, pp. 147–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Sharma, C. Hu, J. L. Brigman, G. Zhu, H. J. Hathaway, and E. R. Prossnitz, “GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state,” Endocrinology, vol. 154, no. 11, pp. 4136–4145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. J. P. Tiano, V. Delghingaro-Augusto, C. Le May et al., “Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes,” The Journal of Clinical Investigation, vol. 121, no. 8, pp. 3331–3342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. L. Irsik, P. K. Carmines, and P. H. Lane, “Classical Estrogen Receptors and ERα splice variants in the mouse,” PLoS ONE, vol. 8, no. 8, Article ID e70926, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. J. C. Stanley, “The regulation of glucose production. The role of liver glycogen and gluconeogenesis in the liver and kidney cortex,” British Journal of Anaesthesia, vol. 53, no. 2, pp. 137–146, 1981. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Barton and E. R. Prossnitz, “Emerging roles of GPER in diabetes and atherosclerosis,” Trends in Endocrinology & Metabolism, vol. 26, no. 4, pp. 185–192, 2015. View at Publisher · View at Google Scholar
  59. N. Yamabe, K. S. Kang, W. Lee, S. Kim, and B. T. Zhu, “Estriol blunts postprandial blood glucose rise in male rats through regulating intestinal glucose transporters,” The American Journal of Physiology—Endocrinology And Metabolism, vol. 308, no. 5, pp. E370–E379, 2015. View at Publisher · View at Google Scholar
  60. A. J. Scheen, B. J. Jandrain, D. M. P. Humblet, C. B. Jaminet, U. J. Gaspard, and P. J. Lefebvre, “Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism,” Fertility and Sterility, vol. 59, no. 4, pp. 797–802, 1993. View at Google Scholar · View at Scopus
  61. R. E. Van Pelt, W. S. Gozansky, R. S. Schwartz, and W. M. Kohrt, “Intravenous estrogens increase insulin clearance and action in postmenopausal women,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 285, no. 2, pp. E311–E317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Ahmed-Sorour and C. J. Bailey, “Role of ovarian hormones in the long-term control of glucose homeostasis glycogen formation and gluconeogenesis,” Annals of Nutrition and Metabolism, vol. 25, no. 4, pp. 208–212, 1981. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Saengsirisuwan, S. Pongseeda, M. Prasannarong, K. Vichaiwong, and C. Toskulkao, “Modulation of insulin resistance in ovariectomized rats by endurance exercise training and estrogen replacement,” Metabolism—Clinical and Experimental, vol. 58, no. 1, pp. 38–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Feigh, K. V. Andreassen, S. T. Hjuler et al., “Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats,” Menopause, vol. 20, no. 7, pp. 785–794, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Nigro, A. T. Santos, C. S. Barthem et al., “A change in liver metabolism but not in brown adipose tissue thermogenesis is an early event in ovariectomy-induced obesity in rats,” Endocrinology, vol. 155, no. 8, pp. 2881–2891, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. S. M. Varas and G. A. Jahn, “The expression of estrogen, prolactin, and progesterone receptors in mammary gland and liver of female rats during pregnancy and early postpartum: regulation by thyroid hormones,” Endocrine Research, vol. 31, no. 4, pp. 357–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. O. Selmin, P. A. Thorne, F. M. Blachere, P. D. Johnson, and D. F. Romagnolo, “Transcriptional activation of the membrane-bound progesterone receptor (mPR) by dioxin, in endocrine-responsive tissues,” Molecular Reproduction and Development, vol. 70, no. 2, pp. 166–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Shima, N. Okeyama, and N. Akamatu, “Effects of oestrogen on adenylate cyclase system and glucose output in rat liver,” Biochemical Journal, vol. 257, no. 2, pp. 407–411, 1989. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Takeda, K. Toda, T. Saibara et al., “Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency,” Journal of Endocrinology, vol. 176, no. 2, pp. 237–246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. E. R. Simpson, M. Misso, K. N. Hewitt et al., “Estrogen—the good, the bad, and the unexpected,” Endocrine Reviews, vol. 26, no. 3, pp. 322–330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Gao, G. Bryzgalova, E. Hedman et al., “Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3,” Molecular Endocrinology, vol. 20, no. 6, pp. 1287–1299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Xie, M.-L. Liu, Y.-P. Gu et al., “Oestrogen improves glucose metabolism and insulin signal transduction in HepG2 cells,” Clinical and Experimental Pharmacology and Physiology, vol. 30, no. 9, pp. 643–648, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Parthasarathy, V. N. Renuka, and K. Balasubramanian, “Sex steroids enhance insulin receptors and glucose oxidation in Chang liver cells,” Clinica Chimica Acta, vol. 399, no. 1-2, pp. 49–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Lundholm, G. Bryzgalova, H. Gao et al., “The estrogen receptor α-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms,” Journal of Endocrinology, vol. 199, no. 2, pp. 275–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. P. J. Espenshade and A. L. Hughes, “Regulation of sterol synthesis in eukaryotes,” Annual Review of Genetics, vol. 41, pp. 401–427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. M. A. Espeland, S. M. Marcovina, V. Miller et al., “Effect of postmenopausal hormone therapy on lipoprotein(a) concentration,” Circulation, vol. 97, no. 10, pp. 979–986, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Di Croce, G. P. Vicent, A. Pecci, G. Bruscalupi, A. Trentalance, and M. Beato, “The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme a reductase gene contains a tissue-specific estrogen-responsive region,” Molecular Endocrinology, vol. 13, no. 8, pp. 1225–1236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Darabi, M. Rabbani, M. Ani, E. Zarean, M. Panjehpour, and A. Movahedian, “Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy,” Gynecological Endocrinology, vol. 27, no. 9, pp. 701–705, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. M. E. E. Jones, A. W. Thorburn, K. L. Britt et al., “Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12735–12740, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. R. P. A. Barros and J.-Å. Gustafsson, “Estrogen receptors and the metabolic network,” Cell Metabolism, vol. 14, no. 3, pp. 289–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Nemoto, K. Toda, M. Ono et al., “Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice,” The Journal of Clinical Investigation, vol. 105, no. 12, pp. 1819–1825, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Moreno, P. Ordoñez, A. Alonso, F. Díaz, J. Tolivia, and C. González, “Chronic 17β-estradiol treatment improves skeletal muscle insulin signaling pathway components in insulin resistance associated with aging,” Age, vol. 32, no. 1, pp. 1–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Ohlsson, N. Hellberg, P. Parini et al., “Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice,” Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 640–645, 2000. View at Publisher · View at Google Scholar
  84. R. D. Feldman, R. Gros, Q. Ding et al., “A common hypofunctional genetic variant of GPER is associated with increased blood pressure in women,” British Journal of Clinical Pharmacology, vol. 78, no. 6, pp. 1441–1452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Hussain, Q. Ding, P. W. Connelly et al., “G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 1, pp. 213–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. S. T. Li, Y. Li, H. Ning et al., “Calcium supplementation increases circulating cholesterol by reducing its catabolism via GPER and TRPC1-dependent pathway in estrogen deficient women,” International Journal of Cardiology, vol. 168, no. 3, pp. 2548–2560, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. B. Chatterjee, C. S. Song, M. H. Jung et al., “Targeted overexpression of androgen receptor with a liver-specific promoter in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 2, pp. 728–733, 1996. View at Publisher · View at Google Scholar · View at Scopus
  88. P. C. Supakar and A. K. Roy, “Role of transcription factors in the age-dependent regulation of the androgen receptor gene in rat liver,” Biological Signals, vol. 5, no. 3, pp. 170–179, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. A. K. Roy, R. L. Vellanoweth, S. Chen et al., “The evolutionary tangle of aging, sex, and reproduction and an experimental approach to its molecular dissection,” Experimental Gerontology, vol. 31, no. 1-2, pp. 83–94, 1996. View at Publisher · View at Google Scholar · View at Scopus
  90. C. M. Wilson and M. J. McPhaul, “A and B forms of the androgen receptor are present in human genital skin fibroblasts,” Proceedings of the National Academy of Sciences, vol. 91, no. 4, pp. 1234–1238, 1994. View at Publisher · View at Google Scholar
  91. C. W. Gregory, B. He, and E. M. Wilson, “The putative androgen receptor-A form results from in vitro proteolysis,” Journal of Molecular Endocrinology, vol. 27, no. 3, pp. 309–319, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Butler, P. N. Leigh, M. J. McPhaul, and J.-M. Gallo, “Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy,” Human Molecular Genetics, vol. 7, no. 1, pp. 121–127, 1998. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Beato, “Gene regulation by steroid hormones,” Cell, vol. 56, no. 3, pp. 335–344, 1989. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Vlahopoulos, W. E. Zimmer, G. Jenster et al., “Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene,” The Journal of Biological Chemistry, vol. 280, no. 9, pp. 7786–7792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. C. D. Foradori, M. J. Weiser, and R. J. Handa, “Non-genomic actions of androgens,” Frontiers in Neuroendocrinology, vol. 29, no. 2, pp. 169–181, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Jacqueson, M. Thevenin, J. M. Warnet, J. R. Claude, and R. Truhaut, “Comparative study of the protective effect of an anabolic steroid. The 19-nortestosterone-phenylpropionate (19 NTPP), on liver steatosis induced by Amanita phalloides and white phosphorus in rats,” Archives of Toxicology Supplement, no. 1, pp. 193–196, 1978. View at Google Scholar
  97. B. Saint-Aubert, P. Vic, C. Brissac et al., “Hepatic regeneration in the rat after subtotal (90%) hepatectomy treated with testosterone,” Comptes Rendus des Séances de l'Académie des Sciences Série D: Sciences naturelles, vol. 291, no. 7, pp. 653–655, 1980. View at Google Scholar
  98. H. Völzke, N. Aumann, A. Krebs et al., “Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men,” International Journal of Andrology, vol. 33, no. 1, pp. 45–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. J. K. Dowman, L. J. Hopkins, G. M. Reynolds et al., “Loss of 5α-Reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice,” Endocrinology, vol. 154, no. 12, pp. 4536–4547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. D. E. W. Livingstone, P. Barat, E. M. Di Rollo et al., “5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents,” Diabetes, vol. 64, no. 2, pp. 447–458, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. D. M. Kelly, J. E. Nettleship, S. Akhtar et al., “Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice,” Life Sciences, vol. 109, no. 2, pp. 95–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. H.-Y. Lin, I.-C. Yu, R.-S. Wang et al., “Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor,” Hepatology, vol. 47, no. 6, pp. 1924–1935, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. Z. Magyar, G. Bekesi, K. Racz et al., “Increased total scavenger capacity and decreased liver fat content in rats fed dehydroepiandrosterone and its sulphate on a high-fat diet,” Gerontology, vol. 57, no. 4, pp. 343–349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Jones, V. S. Sprung, C. J. A. Pugh et al., “Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 10, pp. 3709–3716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. P. A. Schwingel, C. C. Zoppi, and H. P. Cotrim, “Increased liver steatosis in anabolic-androgenic steroid users: more evidence towards toxicant-associated fatty liver disease development,” Liver International, vol. 31, no. 8, pp. 1240–1241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Münzker, D. Hofer, C. Trummer et al., “Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 2, pp. 653–660, 2015. View at Publisher · View at Google Scholar · View at Scopus
  107. H.-Y. Lin, Q. Xu, S. Yeh, R.-S. Wang, J. D. Sparks, and C. Chang, “Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor,” Diabetes, vol. 54, no. 6, pp. 1717–1725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. D. M. Kelly and T. H. Jones, “Testosterone: a metabolic hormone in health and disease,” Journal of Endocrinology, vol. 217, no. 3, pp. R25–R45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. N. Kanaya, S. Vonderfecht, and S. Chen, “Androgen (dihydrotestosterone)-mediated regulation of food intake and obesity in female mice,” Journal of Steroid Biochemistry and Molecular Biology, vol. 138, pp. 100–106, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Bohdanowicz-Pawlak, A. Lenarcik-Kabza, A. Brona et al., “Non-alcoholic fatty liver disease in women with polycystic ovary syndrome—clinical and metabolic aspects and lipoprotein lipase gene polymorphism,” Endokrynologia Polska, vol. 65, no. 6, pp. 416–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  111. E. L. Ding, Y. Song, V. S. Malik, and S. Liu, “Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 295, no. 11, pp. 1288–1299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. N. L. Keating, A. J. O'Malley, S. J. Freedland, and M. R. Smith, “Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer,” Journal of the National Cancer Institute, vol. 104, no. 19, pp. 1518–1523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Grossmann and J. D. Zajac, “Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?” Clinical Endocrinology, vol. 74, no. 3, pp. 289–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Inaba, Y. Otani, K. Nishimura et al., “Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment,” Metabolism: Clinical and Experimental, vol. 54, no. 1, pp. 55–59, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Corona, M. Monami, G. Rastrelli et al., “Type 2 diabetes mellitus and testosterone: a meta-analysis study,” International Journal of Andrology, vol. 34, no. 6, part 1, pp. 528–540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. T. Muthusamy, P. Murugesan, and K. Balasubramanian, “Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat,” Metabolism: Clinical and Experimental, vol. 58, no. 11, pp. 1581–1592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. I. J. Mcewan and J.-Å. Gustafsson, “Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 16, pp. 8485–8490, 1997. View at Publisher · View at Google Scholar · View at Scopus
  118. S. Yeh and C. Chang, “Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 11, pp. 5517–5521, 1996. View at Publisher · View at Google Scholar · View at Scopus
  119. P. Aarnisalo, J. J. Palvimo, and O. A. Jänne, “CREB-binding protein in androgen receptor-mediated signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 5, pp. 2122–2127, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. S. Movérare-Skrtic, K. Venken, N. Andersson et al., “Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice,” Obesity, vol. 14, no. 4, pp. 662–672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Bergamini, “Different mechanisms in testosterone action on glycogen metabolism in rat perineal and skeletal muscles,” Endocrinology, vol. 96, no. 1, pp. 77–84, 1975. View at Publisher · View at Google Scholar · View at Scopus
  122. E. C. Tok, D. Ertunc, C. Evruke, and S. Dilek, “The androgenic profile of women with non-insulin-dependent diabetes mellitus,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 49, no. 9, pp. 746–752, 2004. View at Google Scholar · View at Scopus
  123. J.-Y. Oh, E. Barrett-Connor, N. M. Wedick, and D. L. Wingard, “Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study,” Diabetes Care, vol. 25, no. 1, pp. 55–60, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. B. Andersson, P. Märin, L. Lissner, A. Vermeulen, and P. Björntorp, “Testosterone concentrations in women and men with NIDDM,” Diabetes Care, vol. 17, no. 5, pp. 405–411, 1994. View at Publisher · View at Google Scholar · View at Scopus
  125. K. Højlund, “Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance,” Danish Medical Journal, vol. 61, no. 7, Article ID B4890, 2014. View at Google Scholar · View at Scopus
  126. L. Velez and A. Motta, “Association between polycystic ovary syndrome and metabolic syndrome,” Current Medicinal Chemistry, vol. 21, no. 35, pp. 3999–4012, 2014. View at Publisher · View at Google Scholar
  127. A. F. G. Cicero, E. Tartagni, and S. Ertek, “Metformin and its clinical use: new insights for an old drug in clinical practice,” Archives of Medical Science, vol. 8, no. 5, pp. 907–917, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. M. O. Weickert, P. Hodges, B. K. Tan, and H. S. Randeva, “Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin,” Minerva Endocrinologica, vol. 37, no. 1, pp. 25–40, 2012. View at Google Scholar · View at Scopus
  129. H. Larsson and B. Ahrén, “Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women,” Diabetes Care, vol. 19, no. 12, pp. 1399–1403, 1996. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Maggio, F. Lauretani, G. P. Ceda et al., “Association of hormonal dysregulation with metabolic syndrome in older women: data from the InCHIANTI study,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 1, pp. E353–E358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. N. Gårevik, C. Skogastierna, A. Rane, and L. Ekström, “Single dose testosterone increases total cholesterol levels and induces the expression of HMG CoA Reductase,” Substance Abuse: Treatment, Prevention, and Policy, vol. 7, article 12, 2012. View at Publisher · View at Google Scholar · View at Scopus